Antisense therapy for lymphomas
โ Scribed by Finbarr E. Cotter
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 58 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0278-0232
No coin nor oath required. For personal study only.
โฆ Synopsis
๏ซ๏ฅ๏น ๏ท๏ฏ๏ฒ๏ค๏ณ antisense; BCL-2; apoptosis; lymphoma 'gene silencing', by synthetic oligonucleotides, as a therapeutic tool. In the field of lymphomas obvious targets include follicular lymphoma with the t(14;18) translocation, deregulated expression of the BCL-2 gene, chemoresistance and subsequent protection against lymphoma cell death.
Binding of a sequence-specific oligonucleotide to a targeted length of mRNA should occur with a high level of specificity. The resultant formation of the mRNA-DNA duplex would, if the relevant portion of mRNA has been targeted, suppress the translation of the targeted message into protein. If the production of that protein, such as BCL-2, is essential for the survival of the
๐ SIMILAR VOLUMES
Monoclonal antibodies are an exciting advance in the treatment of lymphoma. They are safe and well-tolerated, and exhibit little cross-resistance with conventional chemotherapeutic agents. In indolent lymphomas, antibody therapy has shown useful response rates, both as first-line therapy and in rela
## Abstract ## Background Aberration in the pattern of DNA methylation is one of the hallmarks of cancer. We present data suggesting that dysregulation of MBD2, a recently characterized member of a novel family of methylated DNA binding proteins, is involved in tumorigenesis. Two functions were as